David Singer

Before joining Maverick in 2004, David was the founding CEO of three startups which all became public companies: Affymetrix (NASDAQ: AFFX), Corcept Therapeutics (NASDAQ: CORT) and Genesoft Pharmaceuticals (NASDAQ: OSCI). As an investor for the past 20+ years, David has served on the boards of 28 private companies including seven that went public during his service. He is Vice Chair of College Track and is a Lecturer at the Stanford Graduate School of Business. In 2023, 2024 and 2025, David was included in Forbes’ Midas List of the world’s best venture capital investors. David holds an M.B.A. from Stanford and a B.A. from Yale University.